Damora Therapeutics, Inc. (DMRA) Stock Price & Analysis
Damora Therapeutics, Inc. (DMRA) rose 0.24% to USD 20.96 as of June 10, 2026 at 09:49 UTC, according to Nexqual real-time market data.
DMRA last closed at USD 20.91; the session ranged USD 20.1–22.22 on volume of 459,938 shares. Market capitalization is $1.29B, with a 52-week range of USD 2.45–38.33 (NCM). Source: Nexqual, June 10, 2026 at 09:49 UTC.
Key Statistics (as of June 10, 2026 at 09:49 UTC)
| Price | USD 20.96 |
|---|---|
| Change | ▲ 0.24% (up) |
| Previous Close | USD 20.91 |
| Open | USD 20.97 |
| Day Range | USD 20.1 – 22.22 |
| 52-Week Range | USD 2.45 – 38.33 |
| Volume | 459,938 shares |
| Market Cap | $1.29B |
| Exchange | NCM |
Technical Analysis (DMRA)
Nexqual's technical model rates DMRA "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.45 (oversold) |
| vs SMA50 | Below (USD 24.87) |
| MACD | -0.84 (negative) |
Analyst Ratings (DMRA)
Wall Street analysts rate DMRA "Strong Buy" based on 7 analysts, with a mean price target of USD 43.14 (range USD 35–51), per Nexqual as of June 10, 2026 at 09:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 43.14 |
| High Target | USD 51 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (DMRA)
| EPS Estimate | USD -0.39 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 09:49 UTC.
Financials & Fundamentals (DMRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -89.50% |
| Current Ratio | 22.49 |
| Total Cash | $532.90M |
| Total Debt | $0 |
| Free Cash Flow | $-8.69M |
Source: Nexqual, June 10, 2026 at 09:49 UTC.
Financial Health Score (DMRA)
Nexqual rates Damora Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $533M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$25M |
| Efficiency | Critical — ROE -90%, ROA -14.7% |
Ownership (DMRA)
| Insider Ownership | +7.69% |
|---|---|
| Institutional Ownership | +91.05% |
| Shares Outstanding | 61.55M |
| Float | 41.22M |
| Short % of Float | +2.66% |
Source: Nexqual, June 10, 2026 at 09:49 UTC.
Leadership (DMRA)
Damora Therapeutics, Inc. is led by Jennifer A. Jarrett (age 54), CEO, President & Director, per Nexqual as of June 10, 2026 at 09:49 UTC.
| CEO, President & Director | Jennifer A. Jarrett (age 54) |
|---|---|
| Chief Operating Officer | Sherwin Sattarzadeh (age 46) |
Major Backers & Investors (DMRA)
Notable institutional backers of Damora Therapeutics, Inc. include FMR, LLC, Fairmount Funds Management LLC, Fidelity, according to Nexqual as of June 10, 2026 at 09:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.7% |
| Fairmount Funds Management LLC | 14.16% |
| Fidelity | 9.62% |
| Avoro Capital Advisors LLC | 6.15% |
| Venrock Adviser, LLC | 5.85% |
| FCPM III Services B.V. | 3.97% |
| RA Capital Management, L.P. | 3.9% |
| Janus Henderson Group PLC | 3.84% |
Source: Nexqual, June 10, 2026 at 09:49 UTC.
From Damora Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
- The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
- It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRAX | Praxis Precision Medicines, Inc | USD 250.33 | ▼ 1.44% |
| EVAX | Evaxion A/S | USD 3.63 | ▲ 2.25% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3 | ▲ 0.67% |
| OLMA | Olema Pharmaceuticals, Inc. | USD 10.45 | ▲ 1.36% |
| PRFX | PRF Technologies Ltd. | USD 1.42 | ▼ 10.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:49 UTC. This page is informational and not investment advice.